Clinical trial NCT04275713: Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC
Official title: Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in Locally Advanced Cervical Cancer.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cervical Cancer
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2020-02-19
Enrollment: 41
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients are randomized to intervention Group (metformin in combination with radiotherapy) or standard of care.
Primary purpose: TREATMENT

Brief summary: Poor tumor oxygenation (hypoxia) is an established negative prognostic and predictive factor in locally advanced cervical cancer (LACC). Hypoxia-modifying measures implemented in the clinic are lacking.

Metformin is a well-known, well-tolerated and low-cost drug used for decades in the treatment of type 2- diabetes. Recent studies suggest an improved tumor oxygenation by metformin potentially improving radiotherapy response and patient outcome.

This study is a randomized, phase II, open label study in patients with LACC where patients are randomized to standard cisplatin-based chemoradiotherapy +/- Metformin.

Metformin will be started one week prior to the start of chemoradiotherapy, and will be continued throughout the entire radiation treatment.

Tumor oxygenation will be evaluated by gene signatures and MRI- parameters.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed cervical cancer (squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma)

  * Planned for radical chemoradiotherapy
  * Over 18 years
  * Speaks and understands Norwegian
  * ECOG 0-1
  * Cervical tumor available for biopsy by gynecological examination
  * Hemoglobin ≥ 9 g/dL (blood transfusions are allowed)
  * Leukocytes ≥ 3,5 x 10\^9/L 18
  * Absolute neutrophil count ≥ 1,5 x 10\^9/L
  * Platelets ≥ 100 x 10\^9/L
  * Total bilirubin ≤ 25 umol/L
  * AST/ALT ≤ 2,5 x institutional upper limit
  * Creatinine ≤ 90 or creatinine clearance ≥ 60 ml/min/1.73m2 Patients with elevated creatinine secondary to hydronephrosis may be eligible if renal function returns to normal after inserting an internal stent or nephrostomy
  * Women of childbearing potential (WOCBP) should have a negative highly sensitive serum pregnancy test within 72 hours prior to receiving the first dose of study medication.

Exclusion Criteria:

* Evidence of distant metastasis. Suspicious paraaortic lymph nodes below the renal vessel are allowed if they are covered by the radiation field
* Patients who have received other cancer treatments for their cervical cancer
* Patients who receive other experimental drugs
* Known diabetes mellitus
* Currently taking Metformin or any other antidiabetic drugs (sulfonylureas, thiazolidinediones, insulin)
* History of allergic reaction attributed to compounds of similar chemical or biologic composition to metformin
* Contraindications such as

  * Hypersensitivity to the active substance or to any of the excipients listed Section 6.1.
  * Severe renal failure (GFR \<30 ml / min).
  * Acute conditions leading to the risk of renal impairment, eg: dehydration, severe infectious conditions, shock.
  * Disease that can cause tissue hypoxia (especially acute illness or exacerbation of chronic illness), such as: acute decompensated heart failure, lung failure, recent heart attack, shock.
  * Liver failure, acute alcohol intoxication, alcoholism.
* Any condition associated with increased risk of metformin- induced lactic acidosis (congestive heart failure defined as New York Heart Association (NYHA) class III or IV functional status, history of acidosis of any kind)
* Uncontrolled intercurrent somatic illness including, but not limited to, ongoing or active serious infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction within 6 months and cerebrovascular disease with previous stroke
* Already on medication with increased risk of lactic acidosis
* Patients who are pregnant or breastfeeding are excluded due to risk of teratogenic and abortifacient effects of radiotherapy and cisplatin, and the potential risk of adverse effect of nursing infants

Primary outcomes:
measure: Metformin dependent changes in hypoxia-related gene expression.
timeFrame: baseline and one week
Secondary outcomes:
measure: Metformin dependent changes in MRI-parameters.
timeFrame: baseline and one week
measure: Metformin dependent change in acute toxicity
timeFrame: baseline, 4 weeks, end of treatment (about 7 weeks), 3 month follow-up
measure: Metformin dependent change in tumor volume during treatment
timeFrame: Baseline and about 4 weeks
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
affiliation: Oslo University Hospital
name: Kjersti Bruheim, PhD
role: PRINCIPAL_INVESTIGATOR
References: